[logo] HealthTree Foundation
search person

Clinical Trial: An Early Study with a New Immunomodulator (CC-220) With or Without Dex for Relapsed/Refractory Multiple Myeloma Patients

Posted: May 01, 2017
Clinical Trial: An Early Study with a New Immunomodulator (CC-220) With or Without Dex for Relapsed/Refractory Multiple Myeloma Patients image

This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as a single therapy and in combination with dexamethasone. CC-220 is a new immunomodulator being developed by Celgene Corporation. The IMiDs are a backbone class of therapies for multiple myeloma. CD-220, also called iberdomide, affects the Cereblon pathway which is one of the mechanisms of action for the immunomodulator drugs. 

There are 3 active sites for this trial: The Mayo Clinic Scottsdale, the Karmanos Cancer Institute and at the Winship Cancer Institute.

Learn more and find the closest trial site here:

CC-220 Clinical Trial

To find all eligible clinical trials for your myeloma, click here: 

Find All Myeloma Clinical Trials

This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as a single therapy and in combination with dexamethasone. CC-220 is a new immunomodulator being developed by Celgene Corporation. The IMiDs are a backbone class of therapies for multiple myeloma. CD-220, also called iberdomide, affects the Cereblon pathway which is one of the mechanisms of action for the immunomodulator drugs. 

There are 3 active sites for this trial: The Mayo Clinic Scottsdale, the Karmanos Cancer Institute and at the Winship Cancer Institute.

Learn more and find the closest trial site here:

CC-220 Clinical Trial

To find all eligible clinical trials for your myeloma, click here: 

Find All Myeloma Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Thanks to our sponsors:
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.